Eli Lilly Pays Eight Figures Annually for Chai Discovery's Biologics Design Model

In a landmark deal structure for AI drug discovery, Lilly commits a mid-eight-figure annual license fee to Chai Discovery for access to its biologics design foundation model. Separately, GSK pays $50M upfront to NOETIK for its oncology model. The era of AI-as-infrastructure-for-pharma is here.

By BT Research